ONO-4538 Multicenter, Open-label, Single-arm, Phase II Study in Advanced Non-small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
- 03 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jul 2017.
- 03 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Apr 2016 Status changed from not yet recruiting to recruiting.